𝔖 Bobbio Scriptorium

✦ LIBER ✦

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB–IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial

✍ Scribed by E. PUJADE-LAURAINE; A. du BOIS; A. GOUPIL; J. ROCHON; V. MÖBUS; B. WEBER; S. OLBRICHT; U. NITZ; M. WARM; B. RICHTER

Book ID: 109085408
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 41 KB
Volume: 15
Category: Article
ISSN: 1048-891X
DOI: 10.1111/j.1525-1438.2005.00439.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line treatment of ovarian/tubal/pe

First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

✍ G.B. KRISTENSEN; I. VERGOTE; G. STUART; J.M. Del CAMPO; J. KÆRN; M. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB

Paclitaxel-carboplatin-gemcitabine (TCG)

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

✍ A. du BOIS; J. SEHOULI; B. LUND; F. JOLY; J. HUOBER; T.S 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB